Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK… Ended

2023-506313-21-00 PD-1 refractory melanoma 9 2020-08-03
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melano… Ended

2023-506314-51-00 Stage IIIB or IIIC or IIID melanoma 9 2020-07-31
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refracto… Ended

2023-506312-41-00 PD-1 refractory melanoma 9 2020-07-30
Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer. Ended

2023-509881-39-00 prostate cancer 4 2020-07-27
Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation … Ended

2023-507222-17-00 Acute Myeloid Leukaemia 5 2020-07-24
Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended

2022-500820-31-00 Recurrent or metastatic squamous cell carcinoma of the 4 2020-07-16
A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors Ended

2024-516351-40-00 Metastatic Castration-Resistant Prostate Cancer 1 2020-07-15
Dose-Escalation Study of Cevostamab in Participants with Relapsed or Refractory Multiple Myeloma Ended

2022-502053-34-00 Multiple Myeloma (MM) 1 2020-07-13
A Study of Lenvatinib for Pediatric Patients with Relapsed or Refractory Solid Tumors Ended

2024-512135-80-00 Between ages 2 and 21 and have High Grade Glioma (HGG), 4 2020-07-13
Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma Ended

2022-502116-36-00 Incurable/Non-metastatic Hepatocellular Carcinoma 5 2020-07-10
“Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Pat… Ended

2024-514206-31-00 Small cell lung cancer (SCLC). 9 2020-07-09
Clinical Trial to evaluate the efficacy of immunotherapy in a subset of Hormonal Receptor-positive/HER2-negative advanced breast cancer pati… Ended

2023-508546-17-00 Pre and post-menopausal women with locally advanced or 4 2020-07-01
A Study of Atezolizumab plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensiv… Ended

2022-502988-37-00 Small cell lung cancer (SCLC) 5 2020-06-19
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended

2023-505035-12-00 RET fusion−positive, metastatic Non-Small Cell Lung Can 5 2020-06-12
Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission … Ended

2023-507221-42-00 Acute Myeloid Leukemia in First Remission 5 2020-06-03
A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with r… Ended

2024-518265-10-01 Relapse/ refractory acute Leukemia 1 2020-06-03
A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with pre… Ended

2024-517166-42-00 Diffuse large B-cell lymphoma (DLBCL) 4 2020-05-29
Study to compare 2 chemotherapy, one with Irinotecan liposome injection in addition to combination of chemotherapy and one with standard che… Ended

2024-518303-21-00 Metastatic Pancreatic Adenocarcinoma 5 2020-05-25
Study of combination of metronomic chemotherapy and reactivator of immune response in inflammatory breast cancer spread to the chest wall. Ended

2023-507365-26-00 Locally recurrent, inoperable, and/or metastatic inflam 4 2020-05-20
A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended

2022-502482-17-00 Non-small cell lung cancer (NSCLC) 5 2020-05-19
A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspheri… Ended

2024-511853-23-00 Peritoneal carcinomatosis (PC) from colorectal carcinom 1 2020-05-12
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Ri… Ended

2023-504036-17-00 Chronic Lymphocytic Leukemia (CLL) 5 2020-05-07
Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended

2023-507024-24-00 Metastatic hormone sensitive prostate cancer 5 2020-05-05
Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended

2022-501972-25-00 Locally Advanced Cervical Cancer 5 2020-04-06